Search

Your search keyword '"Moussab Damlaj"' showing total 12 results
Start Over Author "Moussab Damlaj" Journal bone marrow transplantation
12 results on '"Moussab Damlaj"'

1. Feasibility of early sirolimus cessation post non-myeloablative transplantation in adult patients with severe sickle cell disease

Author

Moussab Damlaj, Bader Alahmari, Ahmed Alaskar, Ayman Alhejazi, Husam Alsadi, Inaam Shehab-Eddine, Abdulrahman Alghamdi, Walid Almashaqbeh, Heba Alshobaki, Isam Mahasneh, Ashwaq Alotaibi, Tahany Alanazi, Maybelle Balili, Mohammed Quarshi, Mazin Ahmed, and Mohsen Alzahrani

Subjects
Adult, Sirolimus, Transplantation, Transplantation Conditioning, Hematopoietic Stem Cell Transplantation, Feasibility Studies, Graft vs Host Disease, Humans, Anemia, Sickle Cell, Hematology
Published
2022

2. Clinical course and outcomes of COVID‐19 in hematopoietic cell transplant patients, a regional report from the Middle East

Author

Riad El Fakih, Mohsen Alzahrani, Abdulaziz Hamadah, Khalil Al-Farsi, Tusneem Elhassan, Mohammed F. Essa, Alfadil Haroon, Reem S. Almaghrabi, Khalid Al Anezi, Naif I. AlJohani, Panayotis Kaloyannidis, Ibraheem H. Motabi, Mouhab Ayas, Ashraf M. Suhebeh, Imran K Tailor, Ahmad Alsaeed, Ahmad Alhuraiji, Murtadha Al-Khabori, Moussab Damlaj, Mahmoud Aljurf, Bader Alahmari, Hani Al Hashmi, Syed Osman Ahmed, Sameer Alamoudi, Ibraheem Abosoudah, Feras Alfraih, and Saud Alhayli

Subjects
medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), medicine.medical_treatment, Disease, medicine.disease_cause, Article, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Humans, Multiple myeloma, Retrospective Studies, Coronavirus, Mechanical ventilation, Transplantation, Hematopoietic cell, SARS-CoV-2, business.industry, Haematopoietic stem cells, Mortality rate, Hematopoietic Stem Cell Transplantation, Clinical course, COVID-19, Cancer, Hematology, Institutional review board, medicine.disease, Transplant Recipients, Lymphoma, surgical procedures, operative, 030220 oncology & carcinogenesis, Infectious diseases, business, 030215 immunology
Abstract

Background: The coronavirus disease‐2019 (COVID‐19) caused by SARS Coronavirus 2 (SARS‐CoV‐2) is a potentially lethal infection. Cancer patients, and specifically hematopoietic cell transplant (HCT) recipients are severely immunocompromised and may be at a higher risk of a complicated course with this infection. We aimed to study the COVID-19 outcomes and severity in post HCT patients. Methods: We retrospectively reviewed post-HCT patients diagnosed with COVID-19 between March 15, 2020, and December 1, 2020 at 10 transplant centers across the Middle East. Results: We identified 91 patients with confirmed SARS-CoV-2 infection across 10 transplant centers. 52 patients were post allo-HCT while the remaining 39 patients were post auto-HCT. The median time from transplant was 14.9 months. Mortality rate was 4.4%. Hospital admission rate was 53%. ICU admission rate was 14%. Mechanical ventilation rate was 10%. Oxygen supplementation rate was 18%. Time from HCT to COVID-19 > 6 months was associated with lower admission rates and lower rates of the “severity” composite endpoint. Antibody responses was seen 67% of evaluable patients. Conclusion: In this series of HCT recipients, we report overall favorable clinical outcomes for patients with COVID-19 and provide preliminary insights into the clinical course of this disease in this specific population. Funding Statement: None Declaration of Interests: None. Ethics Approval Statement: The hospitals’ Institutional Review Board approved the study.

Published
2021

3. Infectious complications in adult sickle cell anemia patients undergoing hematopoietic stem cell transplantation

Author

Nourah Alzughaibi, Mohsen Alzahrani, Ayman Alhejazi, Sumayyah Altamimi, Mohammad Bosaeed, Reem M Ramli, Ahmed Alaskar, Moussab Damlaj, Hind Abdullah, Khadega A. Abuelgasim, Bader Alahmari, and Rahma Alzahrani

Subjects
Oncology, Transplantation, medicine.medical_specialty, business.industry, Internal medicine, medicine.medical_treatment, medicine, MEDLINE, Hematology, Hematopoietic stem cell transplantation, medicine.disease, business, Sickle cell anemia
Published
2021

4. Brentuximab vedotin containing salvage followed by consolidation post autologous hematopoietic stem cell transplantation in high risk relapsed refractory classical Hodgkin lymphoma

Author

Khadega A. Abuelgasim, Ahmed Alaskar, Moussab Damlaj, Bader Alahmari, Mohsen Alzahrani, and Ayman Alhejazi

Subjects
Oncology, Transplantation, medicine.medical_specialty, business.industry, medicine.medical_treatment, Hematology, Hematopoietic stem cell transplantation, Internal medicine, Relapsed refractory, medicine, Classical Hodgkin lymphoma, Brentuximab vedotin, business, medicine.drug
Published
2020

5. Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma

Author

Moussab Damlaj, Giamal Gmati, Ahmed Alaskar, Moataz Khairi, Mohammed H Hommady, Osama Ali, Yousef Alsharhan, Mohsen Alzahrani, Bader Alahmari, Ayman Alhejazi, Hind Salama, Emad Masuadi, and Khadega A. Abuelgasim

Subjects
Adult, Male, Oncology, medicine.medical_specialty, Adolescent, Vinorelbine, Deoxycytidine, Disease-Free Survival, Refractory, Recurrence, Chemoimmunotherapy, Internal medicine, Correspondence, Antineoplastic Combined Chemotherapy Protocols, Humans, Medicine, Ifosfamide, Brentuximab vedotin, Survival rate, Brentuximab Vedotin, Transplantation, business.industry, Hematology, Translational research, Middle Aged, Prognosis, Hodgkin Disease, Gemcitabine, Survival Rate, Clinical trial, Female, Immunotherapy, business, medicine.drug
Published
2019

6. HLA-identical related hematopoietic stem cell transplantation in severe sickle cell disease: age is not a barrier to successful outcome

Author

Mohsen Alzahrani, Samer Ghazi, Ayman Hejazi, Abdulrahman Alsultan, Giamal Gmati, Khadega A. Abuelgasim, Hind Salama, Rodaina Abujoub, Mohammed Sh. Essa, Heba Alshobaki, Enas Basher, Husam Mazin Alsadi, Mazin Ahmed, Bader Alahmari, Moussab Damlaj, and Ahmed Alaskar

Subjects
Transplantation, business.industry, medicine.medical_treatment, Cell, Hematopoietic Stem Cell Transplantation, Hematology, Human leukocyte antigen, Disease, Hematopoietic stem cell transplantation, Anemia, Sickle Cell, medicine.anatomical_structure, Text mining, HLA Antigens, Immunology, Medicine, Humans, business
Published
2021

8. Brentuximab vedotin containing salvage followed by consolidation post autologous hematopoietic stem cell transplantation in high risk relapsed refractory classical Hodgkin lymphoma

Author

Moussab, Damlaj, Khadega A, Abuelgasim, Ayman, Alhejazi, Bader, Alahmari, Ahmed, Alaskar, and Mohsen, Alzahrani

Subjects
Brentuximab Vedotin, Salvage Therapy, Hematopoietic Stem Cell Transplantation, Humans, Neoplasm Recurrence, Local, Hodgkin Disease, Transplantation, Autologous, Stem Cell Transplantation
Published
2020

9. Peripheral hematopoietic stem cell mobilization utilizing growth factors in donors with sickle cell trait is safe and effective

Author

Ahmed Alaskar, Bader Alahmari, Mohsen Alzahrani, Ayman Alhejazi, Samer Ghazi, and Moussab Damlaj

Subjects
Transplantation, Sickle cell trait, business.industry, Hematology, medicine.disease, Peripheral Blood Stem Cells, Peripheral, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Immunology, medicine, business, Hematopoietic Stem Cell Mobilization, 030215 immunology
Published
2018

10. Detection of secondary malignancy following high-dose chemotherapy in germ cell tumors: prospects and limitations

Author

Shahrukh K. Hashmi and Moussab Damlaj

Subjects
Transplantation, business.industry, Secondary Malignancy, Neoplasms, Second Primary, Hematology, Neoplasms, Germ Cell and Embryonal, medicine.disease, 03 medical and health sciences, High dose chemotherapy, 0302 clinical medicine, Text mining, Testicular Neoplasms, Bone Marrow, 030220 oncology & carcinogenesis, Cancer research, Humans, Medicine, Germ cell tumors, business, Retrospective Studies, 030215 immunology
Published
2018

11. Pre-autologous transplantation PET/CT using Deauville criteria is an independent predictor of progression in relapsed refractory classical Hodgkin lymphoma

Author

Moussab Damlaj, Samer Ghazi, A Al Askar, Osama Ali, Giamal Gmati, Ayman Hejazi, Ghulam Syed, Mohsen Alzahrani, Khadega A. Abuelgasim, Tabrez Pasha, and Hind Salama

Subjects
Adult, Male, medicine.medical_specialty, Adolescent, Independent predictor, Transplantation, Autologous, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Refractory, immune system diseases, Positron Emission Tomography Computed Tomography, hemic and lymphatic diseases, Classical Hodgkin lymphoma, Humans, Medicine, Autologous transplantation, Young adult, Transplantation, PET-CT, medicine.diagnostic_test, business.industry, Hematology, Hodgkin Disease, surgical procedures, operative, Positron emission tomography, 030220 oncology & carcinogenesis, Disease Progression, Female, Radiology, Neoplasm Recurrence, Local, business, Nuclear medicine, 030215 immunology
Abstract

High-dose salvage chemotherapy followed by haematopoietic stem cell transplantation (HCT) is the standard of care in transplant eligible relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL).1 Approximately, half of patients receiving HCT will achieve long-term remissions, but relapse remains the most common cause of treatment failure. A number of prior studies investigated the value of pre-HCT positron emission tomography (PET) scan as a predictor of outcome. Considerable heterogeneity is noted within these studies due to methodology of PET interpretation, timeline of the scan prior to HCT and whether further clinical decisions were based on the scan results.2, 3, 4, 5 In light of the above, we examined the impact of pre-HCT PET/CT graded on the five-point scale Deauville criteria on the post-HCT outcome.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results